决胜“十四五” 打好收官战丨渤海明珠新“药”方——天津生物医药产业发展观察

Core Viewpoint - The article highlights the rapid development of the biopharmaceutical industry in Tianjin, emphasizing its innovative capabilities and strategic importance as a key emerging industry supported by national policies [1][2]. Group 1: Technological Innovation - The Tianjin Industrial Biotechnology Research Institute has achieved significant breakthroughs, including a low-carbon microbial synthesis route for starch using acetic acid as a raw material [1][2]. - The city has established over 1,200 various research projects, showcasing its strong technological innovation capabilities [2]. Group 2: Industry Structure and Growth - Tianjin's biopharmaceutical sector includes 33 national-level innovation platforms, comprising 9 national key laboratories and 2 specialized universities [3]. - The biopharmaceutical industry is projected to exceed 90 billion yuan in output value by 2024, with five sub-chains emerging: pharmaceuticals, medical devices, biomanufacturing, traditional Chinese medicine production, and Chinese herbal medicine processing [5]. Group 3: Collaborative Efforts - The establishment of the Radiopharmaceutical Innovation Consortium led by Tianjin Hengrui Medicine integrates resources from universities and research institutions to tackle key technological challenges [5][7]. - The city has implemented comprehensive support measures for the biopharmaceutical industry, creating a full lifecycle support service system from innovation to market access [7]. Group 4: Talent Development - Tianjin is accelerating the construction of a talent ecosystem that supports the entire industry chain, providing a robust foundation for companies like HeYuan Biotechnology [7]. - The first CAR-T cell therapy product developed by HeYuan Biotechnology has been approved for market, reflecting the growing recognition of China's original therapies in international markets [7].